SEHK:9926Biotechs
How Akeso’s IO 2.0 Bispecific Push At Akeso (SEHK:9926) Has Changed Its Investment Story
Akeso recently announced a collaboration with Memorial Sloan Kettering Cancer Center to run a Phase II trial of its PD-1/CTLA-4 bispecific antibody cadonilimab in a perioperative combination regimen for locally advanced, resectable HER2-negative gastric or gastroesophageal junction adenocarcinoma in the United States.
This partnership, alongside Akeso’s broader IO 2.0 and ADC 2.0 pipeline including Phase II work in advanced non-small cell lung cancer, underscores how bispecific backbones are...